Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Medistim AGM Information 2023

Apr 3, 2023

3662_rns_2023-04-03_b508365e-6303-49a7-b82c-571d834bfb64.html

AGM Information

Open in viewer

Opens in your device viewer

Notice of Annual General Meeting in Medistim ASA

Notice of Annual General Meeting in Medistim ASA

(Oslo, 3rd of April 2023) Medistim ASA (OSE: MEDI), a niche market leader

within ultrasound technology with headquarters in Norway, that develops and

commercializes medical equipment for use within cardiac, vascular and transplant

surgery, announces the Annual General Meeting for the company.

The Annual General Meeting will take place on the 24th of April 2023 at 10.00

and is held at Medistim’s offices at Økernveien 94 in Oslo. Attached are the

agenda for the meeting, the voting form and the annual report for 2022. It is

possible to give proxy with and without voting instructions. By using a proxy

with voting instructions, the shareholders will vote on the specific issues

without personal attendance. For further information on the use of proxy, see

general information at the bottom of the notice and enclosed proxy forms.

Attached is also the annual report for 2022 for Medistim ASA in PDF format and

in ESEF format. The report will also be available on the company web

site: www.medistim.com.

About Medistim:

Medistim was established in 1984, and has a track record of profitable growth

over the past >15 years. The company is a pioneer within its segment, and

continues to invest in new product development. Medistim has wholly owned

subsidiaries with sales organizations in the USA, Canada, China, Germany, UK, Spain, Denmark

and Norway, in addition to the about 60 distributors in Europe, Asia, Middle

East, Africa, Canada and South America. For more information, visit the Medistim

home page: www.Medistim.com

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act (Verdipapirhandelloven).

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: [email protected]

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: [email protected]